World Aids Day
The global challenge of HIV/AIDS remains one of the most pressing public health issues today. According to the latest data from UNAIDS, around 38.4 million people worldwide are living with HIV/AIDS, underlining the need for not only medical intervention but also comprehensive awareness, education, and social change. Despite the significant strides made in treatment and prevention, the confusion surrounding the relationship between HIV and AIDS still persists.
Young people have become influential advocates in the fight against HIV/AIDS. Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities. These young activists utilize digital platforms and peer-to-peer education to dispel myths, promote safe practices, and foster supportive environments for those affected by HIV/AIDS.
Dr Gowri Kulkarni, an expert in Internal Medicine, explains that while the terms HIV and AIDS are often used interchangeably, they are distinctly different. "HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, whereas AIDS (Acquired Immunodeficiency Syndrome) is a condition that occurs when HIV severely damages the immune system," she clarifies. To understand the implications of these differences, it's important to explore the fundamental distinctions between the two.
HIV is the virus responsible for attacking the body’s immune system, specifically targeting CD4 cells, which are crucial for the body’s defense against infections. As HIV progresses, it destroys these cells, weakening the immune system over time. If left untreated, this continuous damage can lead to AIDS.
AIDS, on the other hand, is a syndrome, not a virus. Dr Kulkarni further elaborates that AIDS is a collection of symptoms and illnesses that emerge when the immune system is severely compromised due to prolonged HIV infection. It represents the most advanced stage of HIV, and is characterized by very low CD4 counts or the onset of opportunistic infections like tuberculosis, pneumonia, or certain cancers.
A key distinction to remember is that not everyone with HIV will progress to AIDS. Thanks to advancements in medicine, particularly antiretroviral therapy (ART), individuals living with HIV can manage the virus and maintain a healthy immune system for many years, or even decades, without ever developing AIDS. ART works by suppressing the virus to undetectable levels, effectively preventing the damage HIV would otherwise cause to the immune system.
Without treatment, however, HIV progresses through three stages:
- Acute HIV Infection: This stage occurs shortly after transmission and may include symptoms like fever, fatigue, and swollen lymph nodes.
- Chronic HIV Infection: Often asymptomatic or mildly symptomatic, the virus continues to damage the immune system but at a slower rate.
- AIDS: This is the final stage, marked by severe immune damage and the presence of infections that take advantage of the compromised immune defenses.
Another key distinction between HIV and AIDS is the way in which they are transmitted. HIV is highly contagious and can be transmitted through the exchange of bodily fluids such as blood, semen, vaginal fluids, and breast milk. It is primarily spread through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding.
AIDS, however, is not transmissible. It is not a disease that can be passed from one person to another. Rather, AIDS is the result of untreated, advanced HIV infection and is a direct consequence of the virus’s damage to the immune system.
HIV and AIDS are diagnosed through different methods. HIV is diagnosed through blood tests or oral swabs that detect the presence of the virus or antibodies produced by the immune system in response to the virus. Early detection of HIV is crucial, as it allows for timely intervention and treatment, which can prevent the virus from progressing to AIDS.
AIDS, on the other hand, is diagnosed using more specific criteria. Dr Kulkarni notes that the diagnosis of AIDS is made when the individual’s CD4 cell count falls below 200 cells/mm³, or when opportunistic infections or certain cancers (such as Kaposi's sarcoma or lymphoma) are detected. Diagnosing AIDS involves a more thorough assessment of the individual’s immune function and overall health, as opposed to just the detection of HIV.
The treatment goals for HIV and AIDS differ significantly, although both involve antiretroviral therapy (ART). For HIV, the primary treatment goal is to suppress the virus to undetectable levels, thus maintaining a strong immune system and preventing further transmission of the virus. People living with HIV can often live long, healthy lives if they adhere to ART.
For individuals diagnosed with AIDS, the treatment plan becomes more complex. While ART remains an essential part of managing the virus, treatment for AIDS also focuses on addressing the opportunistic infections and secondary health complications associated with severe immune suppression. The goal of treatment for AIDS is not only to manage the HIV virus but also to improve the quality of life and extend survival by treating these secondary health issues.
While the medical community has made great strides in managing HIV, the battle to curb its transmission is also a social and cultural issue. Dr Daman Ahuja, a public health expert, highlights that HIV/AIDS awareness and education are vital to reducing transmission rates and supporting those affected by the virus. "Young people, especially, have become key advocates in the fight against HIV/AIDS," says Dr Ahuja. "Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities."
Additionally, grassroots activism plays a significant role in raising awareness and addressing stigma. As the World Health Organization reports, community-based interventions have been proven to increase HIV testing rates and improve treatment adherence, which are crucial in the fight against the pandemic.
The ultimate goal of organizations like UNAIDS is to eliminate the HIV/AIDS pandemic by 2030. Achieving this requires global collaboration, from medical treatment advancements to public health strategies, education, and advocacy. Dr Kulkarni’s insight underscores the importance of early detection, treatment adherence, and community support in the fight against HIV/AIDS.
Dr Gowri Kulkarni is Head of Medical Operations at MediBuddy and Dr Daman Ahuja, a public health expert and has been associated with Red Ribbon Express Project of NACO between 2007-12.
Credits: GoFundMe
For most parents, the toddler years are filled with first words, wobbly steps and dreams of the future. For Gus and Emily Forrester, those moments are now overshadowed by a diagnosis they describe as “every parent’s worst nightmare.”
Their two-year-old daughter, Leni, has been diagnosed with Sanfilippo Syndrome Type B, a rare genetic condition often referred to as childhood dementia. The disorder, formally known as Mucopolysaccharidosis type III, gradually robs children of their physical and cognitive abilities.
In an interview with ITV News, Leni’s parents spoke about the devastating reality of the condition, which has no approved cure or widely available treatment.
“All your dreams for your child's future are taken away,” her mother, Emily, said. “To be told that she has this condition, and there is no treatment and no cure and no support… it’s completely earth-shattering.”

Sanfilippo Syndrome is a neurodegenerative disorder caused by the body’s inability to break down certain complex sugars. Over time, these substances build up in the brain, leading to progressive damage.
According to Cure Sanfilippo Foundation, symptoms usually begin appearing between the ages of one and six. Children may initially show mild developmental delays, but the disease gradually worsens, affecting speech, mobility and behaviour.
As the condition advances, many children lose the ability to talk, walk and recognise loved ones. Life expectancy is often limited to the early teenage years.
Emily explained the process in stark terms. Without treatment, she said, Leni’s body will slowly be overwhelmed by “toxic waste,” causing irreversible damage.
For families like the Forresters, time is not just precious, it is critical.
“Early treatment is key for these children,” Emily said. “If she has to wait six months, that could mean she can no longer talk. If she waits 12 months, that could mean she loses the ability to walk.”
Although experimental therapies, including gene-based approaches, are being developed, access remains a major hurdle. Some clinical trials are expected to take place in the United States later this year, but Leni is not currently eligible.
Her parents are now campaigning for UK patients to be included in these trials, arguing that promising science already exists but remains out of reach for many families.
In response to the diagnosis, the Forresters have launched a fundraiser to support Leni’s care and potential treatment options. They have also pledged to donate part of the funds to Great Ormond Street Hospital, where Leni is receiving care, and to the Cure Sanfilippo Foundation, which supports affected families.
So far, donations have crossed $250,000, reflecting the growing awareness and concern around rare childhood conditions.
Leni’s father, Gus, said the emotional toll of the diagnosis is hard to put into words. “As parents, your role is to protect your children and provide every opportunity you can. Without any treatment, her future and her reality is very, very dark.”
Beyond fundraising, the couple is also raising awareness about childhood dementia and advocating for newborn screening programmes that could help detect such conditions earlier.
Experts working on experimental therapies say greater government investment is urgently needed. Without it, many children may never benefit from treatments that could slow or alter the course of the disease.
For now, Leni remains a cheerful two-year-old, full of life and affection. But for her parents, every passing day is a reminder of how quickly that could change, and how urgently answers are needed.
Every year, March 24 is observed as World Tuberculosis Day to spread awareness about the infectious disease. In India, it remains one of the most pressing infectious diseases. Dr Arup Halder, Consultant Pomologist at CK Birla Hospitals, CMRI says that India still accounts for roughly a quarter to over a quarter of world's tuberculosis or TB cases. "In 2023–2024, India reported around 25–26 lakh TB patients out of an estimated 27 lakh cases, reflecting improved detection but also highlighting a persistently high burden," he points out.
Also Read: Harish Rana Taken Off Food And Water Support For Over 10 Days; Waiting For Passive Euthanasia
While TB incidence has fallen by about 20 per cent since 2015 and mortality has also declined to roughly 21 deaths per lakh population, it still remains well above national elimination targets for 2025.
What makes TB so difficult to eliminate? While many associate TB with persistent coughing, studies show that 80 per cent of patients do not show the symptoms of cough that is "presumed" to be a common symptom. This is why, TB could go ignored until it is too late.
A research led by Amsterdam UMC and the Amsterdam Institute for Global Health and Development analyzed data on more than 600,000 individuals in Africa and Asia and found that around 82.8 per cent of those with TB had no persistent cough. The study also found that 62.5 per cent had no cough at all. The findings were published in the Lancet Infectious Diseases.
Also Read: Perez Hilton Spent 21 Days In Hospital After Taking Medication on an Empty Stomach
The study in fact noted that this could be the "probable reason why, despite huge efforts to diagnose and treat the disease, the tb burden across Africa and Asia is hardly declining". Frank Cobelens, Professor of Global Health at Amsterdam UMC and Senior Fellow at the AIGHD says, "A persistent cough is often the entry point for a diagnosis, but if 80 per cent of those with TB do not have one, then it means that a diagnosis will happen later, possibly after the infection has already been transmitted to many others, or not at all."
Another 2019 study published in Elsevier notes: "Coughing does not appear to be a necessary prerequisite for TB transmission." The study further mentions, "Frequency of cough is associated with infectivity but this does not imply mechanistic causality for TB transmission."
The simple answer to this is: No. Coughing does not mean harmless, especially when it is a persistent one. The study only shows that TB does not always mean persistent coughing, however, if one experiences this symptom, they should always get a test done and should not ignore the symptoms.
Researchers from The University of Texas at Dallas' Center for Advanced Pain Studies working with colleagues from UT Southwestern Medical Center note that TB coughing could cause pain. This is one of the way one can distinguish the symptoms. The findings published in journal Cell notes that before this study, "no one had even shown that TB produces an irritant that acts directly on the sensory innervation of the lungs".
Corresponding author Dr Michael Shiloh, associate professor of internal medicine and microbiology at UT Southwestern said, "People with active tuberculosis can cough for months and spread disease even when they are receiving appropriate treatment."
Read: World Tuberculosis Day 2026: Theme, Origin, And Significance
On World TB Day, President Droupadi Murmu stressed that TB continues to pose a significant public health challenge and has affected millions of lives across the world. She urged all stakeholders to work together with collective resolve to end TB once for all.
To act on it, Union Health Minister Jagat Prakash Nadda will launch a series of initiatives, including 'TB Mukt Bharat Abhiyaan - 100 Days Campaign', the TB Mukt Bharat App, and the TB Mukt Urban Ward Initiative. These measures are designed to strengthen the case detection, improve treatment adherence, and enhance last-mile delivery of TB services, especially in high-burden areas. The initiatives have also been aligned with the objectives of the National Tuberculosis Elimination Programme.
Credit: Canva
From physical problems like fatigue and vision problems, people who survive the deadly bacterial meningitis are likely to live with long-term fatigue and vision problems, as well as be at high risk of suicide, according to a new study.
The study comes as the UK is experiencing an outbreak of meningitis in Kent, that began among students who visited Club Chemistry in Canterbury between March 5 and 7.
Although bacterial meningitis is treatable, it requires prompt, often immediate treatment for better recovery. Yet patients are likely to face the risk of fatal or long-term complications -- from physical, psychological, and social impacts, said researchers from the University of Otago, The Conversation reported.
The new findings, based on 16 cases from New Zealand, who reportedly suffered the fatal disease, showed that multiple chronic after-effects is permanent in some, while in others, it dragged on for years. The effects include:
"Our findings demonstrate that bacterial meningitis is much more than a life-threatening infection. It is an acute disease with serious, chronic after-effects which are poorly understood and often go unrecognised," the researchers said.
The bug that causes the infection has been identified as the known strain of meningitis B, and MenB vaccines will be offered to 5,000 students living in the University of Kent halls of residence in Canterbury.
Meanwhile, the UKHSA chief executive, Susan Hopkins, said the outbreak "looks like a super-spreader" event with "ongoing spread" through universities' halls of residence.
"There will have been some parties, particularly around this, so there will have been lots of social mixing. I can't yet say where the initial infection came from, how it's got into this cohort, and why it's created such an explosive amount of infections," she added.
As per Trish Mannes, UKHSA Regional Deputy Director for the South East, even after two doses, the MenB vaccine “does not protect against all strains of meningococcal disease, nor against all infections that can cause meningitis. It also does not prevent the bacteria from being carried and spread in the community”.
The UKHSA thus warned people to be aware of the signs and symptoms of invasive meningococcal disease, and to seek immediate medical attention if they or anyone they know develops these signs and symptoms.
Common symptoms include:
© 2024 Bennett, Coleman & Company Limited